5,7-Dimethoxyflavone Attenuates Obesity-Associated Muscle Atrophy via AMPK and PI3K/Akt Pathways in <i>ob/ob</i> mice. [PDF]
Kim MB +4 more
europepmc +1 more source
Abstract Purpose The purpose of this article is to serve as the first of a two‐part review on the meniscus; in this review, we will establish the background on anatomy and pathogenesis of the meniscus, as well as the effect of the meniscus on native knee kinematics and function.
Ehab M. Nazzal +13 more
wiley +1 more source
Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. [PDF]
Lempesis IG, Dalamaga M.
europepmc +1 more source
Abstract Purpose To compare the 2‐year incidence of (1) revision due to periprosthetic joint infection (PJI) and (2) all‐cause revision after primary knee arthroplasty (KA) in patients with/without obesity and to compare the microbial profiles in early (≤ 90 days) and late (91–730 days) PJI.
Saber M. Aljuboori +4 more
wiley +1 more source
Beyond Inflammation - A Multidisciplinary Approach to Managing Obesity and Cardiometabolic Risk in Inflammatory Bowel Disease. [PDF]
Plush SL +6 more
europepmc +1 more source
Abstract Purpose Obesity is a major risk factor for knee osteoarthritis (KOA). Bariatric surgery (BAS) effectively induces weight loss, but some of these patients subsequently require knee arthroplasty (KA) despite substantial weight reduction. However, the impact of prior BAS on the risk of reintervention, antibiotic use and mortality following KA ...
Saber Muthanna Aljuboori +5 more
wiley +1 more source
Nanomaterial-driven modulation of lipid metabolism: Novel strategies toward precision obesity treatment. [PDF]
Zhang S +6 more
europepmc +1 more source
Beyond diabetes and obesity: GLP-1 receptor agonists as multifunctional therapeutics across the steatotic liver disease spectrum. [PDF]
Mahalingam S +3 more
europepmc +1 more source
Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence. [PDF]
Parlati AL +6 more
europepmc +1 more source
Cardiometabolic 2.0: Redefining Cardiovascular Prevention Through SGLT-2 Inhibitors and GLP-1 Receptor Agonists. [PDF]
Tanasescu MD +5 more
europepmc +1 more source

